Medical Science Research Bulletin

Introduction: Darier and Ferrand dermatofibrosarcoma is a locally malignant soft-tissue sarcoma with a high recurrence rate and rare metastasis, first described in 1924. 

Results: This retrospective study analyzes 20 cases of chest wall dermatofibrosarcoma treated at Hassan II University Hospital in Fez from 2009 to 2023. The median patient age was 44.95 years, with a slight female predominance. Tumors varied in size and presentation, commonly appearing as multi-nodular or ulcerating masses. Histological analysis showed spindle-shaped cells with CD34 expression. Surgical treatment involved wide excision with a 5 cm safety margin, followed by reconstruction using skin grafting or directed healing. 

Conclusion: Over an average follow-up of 23 months, no recurrences were observed, highlighting the importance of early diagnosis and multidisciplinary management to improve outcomes and minimize the need for complex surgical repairs.

Cutaneous tumor, Chest wall, Histopathology, Excision, Reconstruction

1. Janczewski L, Wayne J. Contemporary management of dermatofibrosarcoma protuberans. Adv Oncol. 2024;4:1-6. doi:10.1016/j.yao.2023.12.001.
2. DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans. Cancer. 2004;100(7):1008-1016.
3. Maire G, Fraitag S, Galmiche L, et al. A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol. 2007;143(2):203-210.
4. Bendix-Hansen K, Myhre-Jensen O, Kaae S. Dermatofibrosarcoma protuberans. A clinico-pathological study of nineteen cases and review of world literature. Scand J Plast Reconstr Surg 1983; 17: 247–252.
5. Monnier D, Vidal C, Martin L, et al. Dermatofibrosarcoma protuberans: A population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. J Eur Acad Dermatol Venereol. 2006;20(10):1237-1242.
6. Johnson-Jahangir H, Ratner D. Advances in management of dermatofibrosarcoma protuberans. Dermatol Clin. 2011;29(2):191-200.
7. Vitiello GA, Lee AY, Berman RS. Dermatofibrosarcoma protuberans: what is this? Surg Clin North Am. 2022;102(4):657-665. doi:10.1016/j.suc.2022.05.004.
8. Kahn HJ, Fekete E, From L. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison of CD34 and factor XIIIa. Hum Pathol. 2001;32:50-56.
9. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: results of multi-institutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37:600-613.
10. Dermatofibrosarcoma Protuberans, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Available at: www.nccn.org.
11. Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004;30:341-345.
12. Mullen JT. Dermatofibrosarcoma protuberans. Surg Oncol Clin North Am. 2016;25(4):827-839.
13. DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans. Cancer. 2004;100(5):1008-1016.
14. Molina AS, Duprat Neto JP, Bertolli E, et al. Relapse in dermatofibrosarcoma protuberans: A histological and molecular analysis. J Surg Oncol. 2018;117(5):845-850.